FSH and LH elevation after radiation for treatment of cancer of the prostate.
Regional radiation treatment of prostatic carcinoma produced significant increases in serum follicle-stimulating hormones at 3 and 12 months posttreatment from 6.5 +/- 0.5 to 15.9 +/- 0.9 mIU per ml and 19.5 +/- 1.2 mIU per ml (X +/- SE) respectively. Serum luteinizing hormone also increased at 3 months from 4.5 +/- 0.4 to 6.1 +/- 0.5 mIU per ml (X +/- SE). There were no changes in sex steroid-binding globulin, testosterone, or prolactin. The data indicate damage to the testes as a result of scatter from radiation treatment to the prostate.
D000230:Adenocarcinoma / Q000378:metabolism / Q000473:pathology / Q000532:radiotherapy*; D005640:Follicle Stimulating Hormone / Q000097:blood*; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood*; D008297:Male; D011388:Prolactin / Q000097:blood; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000378:metabolism / Q000473:pathology / Q000532:radiotherapy*; D013739:Testosterone / Q000097:blood; D013997:Time Factors; D014156:Transcortin / Q000097:blood
D013739:Testosterone; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D014156:Transcortin